Atyr Pharma INC 8-K filings

aTyr Pharma announced Q2 2026 results, a 60% workforce reduction, and program prioritization to focus on its efzofitimod program for interstitial lung disease, extending cash runway into late 2028.

aTyr Pharma and Kyorin Pharmaceutical have mutually agreed to terminate their collaboration and license agreement, with aTyr regaining exclusive global rights to efzofitimod.

aTyr Pharma has secured an additional 180 days, until November 30, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.

aTyr Pharma presented an investor presentation detailing the advancement of its lead product candidate, efzofitimod, for pulmonary sarcoidosis and other interstitial lung diseases, highlighting trial insights and future development plans.

aTyr Pharma announced Q1 2026 results, detailing progress on efzofitimod development for pulmonary sarcoidosis and SSc-ILD, with a cash position of $68.3 million.

aTyr Pharma announces updated development plan for efzofitimod in pulmonary sarcoidosis following FDA Type C meeting, focusing on a new Phase 3 study with FVC as the primary endpoint.

aTyr Pharma announced its full year 2025 financial results and a corporate update, including the Phase 3 EFZO-FIT study failing to meet its primary endpoint for pulmonary sarcoidosis.

aTyr Pharma, Inc. received a deficiency notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

aTyr Pharma reported third quarter 2025 financial results and a corporate update, including the Phase 3 EFZO-FIT study failing its primary endpoint in pulmonary sarcoidosis.

aTyr Pharma announced that its Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint, though secondary endpoints showed clinical improvements.

aTyr Pharma reports second quarter 2025 financial results and corporate updates, with key Phase 3 clinical trial data anticipated in mid-September.

aTyr Pharma reports Q2 2025 financial results, anticipates Phase 3 EFZO-FIT topline data in mid-September, and shows positive interim Phase 2 EFZO-CONNECT results.

aTyr Pharma reports Q1 2025 results, highlighting progress in its efzofitimod clinical program and upcoming topline data from the Phase 3 EFZO-FIT study in pulmonary sarcoidosis.

aTyr Pharma's stockholders approved an amendment to the company's 2015 Stock Option and Incentive Plan at the 2025 Annual Meeting, increasing the number of shares available for issuance.

aTyr Pharma reports completion of enrollment in Phase 3 EFZO-FIT study for pulmonary sarcoidosis and anticipates topline data in Q3 2025.

aTyr Pharma has amended its sales agreement with Jefferies LLC, increasing the potential offering amount for its common stock.

aTyr Pharma has appointed Eric Benevich to its Board of Directors and amended its Non-Employee Director Compensation Policy.

aTyr Pharma announced the completion of enrollment in its Phase 3 EFZO-FIT study for pulmonary sarcoidosis and provided a corporate update, including financial results for the third quarter of 2024.

aTyr Pharma announced the completion of enrollment in its Phase 3 EFZO-FIT study for pulmonary sarcoidosis and provided a corporate update, including financial results for the second quarter of 2024.

aTyr Pharma has completed enrollment in its Phase 3 clinical trial for efzofitimod in pulmonary sarcoidosis, with topline data expected in the third quarter of 2025.

aTyr Pharma's stockholders approved an increase in shares available under the 2015 Stock Option and Incentive Plan and amendments to the Code of Business Conduct and Ethics at the 2024 Annual Meeting.

aTyr Pharma announced its first quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical trials and a strong cash position.

aTyr Pharma reports its 2023 financial results, highlights clinical trial progress, and announces an expanded access program for its lead drug candidate, efzofitimod.